GlaxoSmithKline plc's meningitis B vaccine, Bexsero, received its second breakthrough therapy designation in the U.S.
The U.S. Food and Drug Administration had previously granted the designation for the prevention of the invasive meningococcal disease in individuals 10 years to 25 years old.
The new designation covers children 2 years to 10 years of age and will help expedite the development and review of the vaccine.
Meningitis B is a life-threatening bacterial infection that causes inflammation in tissues surrounding the brain and spinal cord.
